skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

18 Total results for product and free and sample content found

Awareness

MS Outlook 2020 Scrip 100

24 Jul 2019

Outlook 2020 is the annual look at the performance and future prospects of the global pharmaceutical industry. This year, the supplement will reach more people than ever before with distribution to In Vivo, Pink Sheet, Scrip, Medtech Insight and Generics bulletin subscribers PLUS events such as Biotech Showcase and Partnerships in Clinical Trials.

Topic Deal trends BioPharmaceutical Business strategies

Single report

Pink Sheet

The Drug Pricing Article Pack

15 Jul 2019

Get expert insights into the events driving drug pricing polices around the world.  This Article Pack covers drug pricing issues for: The EU - Vital developments for Norway, Denmark, and other EU countries, including the UK The US – Essential drug pricing info from a country where the issue has taken center stage Australia – Developments surrounding drug pricing issues in Australia

Topic Deal trends Policy and regulation

Single report

Pink Sheet

The Drug Pricing Debate Article Pack

15 Jul 2019

Get expert insights into the events driving drug pricing polices around the world.  This article pack covers drug pricing issues for: The EU - Vital developments for Norway, Denmark, and other EU countries, including the UK The US – Essential drug pricing info from a country where the issue has taken center stage Australia – Developments surrounding drug pricing issues in Australia

Topic Policy and regulation Drug development landscape Deal trends

Single report

Datamonitor Healthcare

Top 10 Best Selling Drugs of 2018 Fund US and EU Pharma RD

15 Jul 2019

Our latest whitepaper lists the top selling drugs last year, who developed them and the strategies behind their success. We drew from three of our top products to create our most recent whitepaper, Datamonitor Health Care, Biomedtracker and Pharmaprojects. You can experience them all for yourself. 

Topic Drug review Strategy Deal trends

View white paper

Pink Sheet

Lessons From Mercosur Multi-Country Pricing Negotiations

By Francesca Bruce 05 Jul 2019

Latin American joint price negotiations have proved successful and other countries are taking note.

Topic Business strategies Deal trends

View article

Scrip

Under The Radar Potential Small Cap Takeover Targets

By Joseph Haas 03 Jul 2019

Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.

Topic Business strategies BioPharmaceutical Deal trends

View article

Scrip

India’s Top Court Tells Singhs To Come Up With Plan To Pay Daiichi, Uphold Nation’s ‘Honor’

By Penelope MacRae 02 Jul 2019

India’s Supreme Court has told Malvinder Singh and Shivinder Singh, once corporate billionaires, to work out a strategy within two weeks to pay Japanese drug giant Daiichi Sankyo a $500m arbitration award and "uphold the nation’s honor."

Topic Business strategies Deal trends

View article

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Topic Deal trends

Single report

Medtrack

Maximizing Royalty Rate Opportunities in Pharma Licensing

By Steven Muntner 16 Sep 2017

Royalty payments are an essential component of most pharmaceutical deals. Along with upfront payments and milestones, companies are rewarded for surpassing certain developmental hurdles.

Topic Deal trends Medtech

Single report
Show More

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now